Min Kang, MD
Neurology · Boston, MANPI 1750725933
Payments from drug & device makers
Across 114 payments — averaging $1935.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$134K
- UCB SA$48K
- UCB, Inc.$22K
- AstraZeneca$14K
- Samsung Bioepis Co., Ltd.$3K
- Johnson & Johnson$169
- plus $151 from 4 others
What the payments were for
- Consulting fees$36,66188%
- Speaking & faculty fees$2000%
- Travel & lodging$3,0317%
- Food & beverage$1,7314%
- Education$840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 52 | $134,189 |
| UCB SA | 14 | $47,527 |
| UCB, Inc. | 23 | $21,728 |
| AstraZeneca | 17 | $13,992 |
| Samsung Bioepis Co., Ltd. | 2 | $2,940 |
| Johnson & Johnson | 2 | $169 |
| Amgen | 1 | $75 |
| Bayer | 1 | $28 |
| Biogen | 1 | $26 |
| Janssen Scientific Affairs, LLC | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$220,696 in reported general payments places this provider in the 85th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 16 | $170,460 |
| Aimovig AutoinjectorErenumab-Aooe | 62 | $52,794 |
| Nurtec OdtRimegepant Sulfate | 26 | $37,111 |
| UbrelvyUbrogepant | 15 | $16,977 |
| Pyridostigmine Bromide | 32 | $7,784 |
| Mycophenolate Mofetil | 39 | $2,997 |
| Gabapentin | 63 | $706 |
| Pregabalin | 44 | $701 |
| Oxcarbazepine | 18 | $676 |
| Duloxetine Hcl | 35 | $663 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 23 | $594 |
| Sumatriptan | 14 | $584 |
| Nortriptyline Hcl | 34 | $549 |
| Prednisone | 42 | $431 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 16 | $292 |
Paid to pharmacies, not to this prescriber.
Other neurology in Boston
- Stephanie RutrickBoston$31.4M
- Scott PlotkinBoston$26.3M
- Patrick WenBoston$18.2M
- James BerryBoston$8.9M
- Isabel Arrillaga-RomanyBoston$8.2M
- Mahmut GurolBoston$7.4M
- Gad MarshallBoston$6M
- Shawn MurphyBoston$5.9M
- Suma BabuBoston$5.8M
- Luis Gonzalez CastroBoston$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.